## Sundeep Kaul

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/746423/publications.pdf

Version: 2024-02-01

		1478505	1720034
9	169	6	7
papers	citations	h-index	g-index
9	9	9	205
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use. Journal of Cardiovascular Pharmacology, 2020, 76, 4-22.	1.9	49
2	Levosimendan Efficacy and Safety: 20 years of SIMDAX in Clinical Use. Cardiac Failure Review, 2020, 6, e19.	3.0	37
3	Autoptic identification of disseminated mucormycosis in a young male presenting with cerebrovascular event, multi-organ dysfunction and COVID-19 infection. IDCases, 2021, 25, e01172.	0.9	32
4	Non-Invasive Ventilation (NIV) in the Clinical Management of Acute COPD in 233 UK Hospitals: Results from the RCP/BTS 2003 National COPD Audit. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2009, 6, 171-176.	1.6	24
5	Short-Term Therapies for Treatment of Acute and Advanced Heart Failure—Why so Few Drugs Available in Clinical Use, Why Even Fewer in the Pipeline?. Journal of Clinical Medicine, 2019, 8, 1834.	2.4	14
6	COVID-19-Associated Pulmonary Mucormycosis. Journal of Fungi (Basel, Switzerland), 2022, 8, 711.	3.5	10
7	Gastrointestinal Tolerance and Protein Absorption Markers with a New Peptide Enteral Formula Compared to a Standard Intact Protein Enteral Formula in Critically Ill Patients. Nutrients, 2021, 13, 2362.	4.1	3
8	2279. Study of Prescribing patterns and Effectiveness of Ceftolozane–tazobactam (C/T): Real-world Analysis (SPECTRA): a multi-national, multicenter observational study. Open Forum Infectious Diseases, 2019, 6, S780-S781.	0.9	0
9	1612. Evaluation of the Use of Ceftolozane/Tazobactam for the Treatment of ESBL-producing Enterobacterales Infections Using International Data from SPECTRA (Study of Prescribing Patterns) Tj ETQq1 1 (2020, 7, S800-S800.	0.784314	rgBT /Overlo